Intravenous fosfomycin for the treatment of hospitalized patients with serious infections

Expert Review of Anti-Infective Therapy

Volumn 15, Issue 10, 2017, Pages 935-945

  Shorr, Andrew F ^a   Pogue, Jason M ^b   Mohr, John F ^c  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b SINAI GRACE HOSPITAL   (United States)

^c Medical Affairs Strategic Solutions ^*  (United States)

Author keywords

critically ill; efficacy; Fosfomycin; ICU; pharmacokinetic; safety; sepsis

Indexed keywords

COLISTIN; DAPTOMYCIN; DORIPENEM; FOSFOMYCIN; IMIPENEM; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; ANTIINFECTIVE AGENT;

ABDOMINAL ABSCESS; ACINETOBACTER INFECTION; ACUTE PYELONEPHRITIS; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERICIDAL ACTIVITY; BLOODSTREAM INFECTION; BONE INFECTION; CRITICALLY ILL PATIENT; CYSTITIS; DRUG CEREBROSPINAL FLUID LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG PENETRATION; ENDOCARDITIS; ENTEROBACTERIACEAE INFECTION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEALTH CARE ASSOCIATED PNEUMONIA; HOSPITAL PATIENT; HUMAN; HYPERNATREMIA; HYPOKALEMIA; INFECTION; INFECTIOUS ARTHRITIS; LOWER RESPIRATORY TRACT INFECTION; MAXIMUM PLASMA CONCENTRATION; MENINGITIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MINIMUM PLASMA CONCENTRATION; MONOTHERAPY; MULTIDRUG RESISTANCE; NONHUMAN; OSTEOMYELITIS; PNEUMONIA; PSEUDOMONAS INFECTION; PYELONEPHRITIS; REVIEW; SEPSIS; SEPTIC SHOCK; SINGLE DRUG DOSE; URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA; VOLUME OF DISTRIBUTION; BACTERIAL INFECTION; HOSPITALIZATION; INTRAVENOUS DRUG ADMINISTRATION; MICROBIOLOGY;

ADMINISTRATION, INTRAVENOUS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; FOSFOMYCIN; HOSPITALIZATION; HUMANS; INPATIENTS;

EID: 85030655909     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1080/14787210.2017.1379897     Document Type: Review

References (56)

1. Jim O'Neil. Review on antimicrobial resistance: tackling drug-resistant infections globally: final report and recommendations. 2016. https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf
2. Dasgupta S, Das S, Chawan NS, et al. Nosocomial infections in the intensive care unit: incidence, risk factors, outcome and associated pathogens in a public tertiary teaching hospital of Eastern India. Indian J Crit Care Med. 2015;19(1):14–20.
3. Parker SL, Lipman J, Koulenti D, et al. What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review. Int J Antimicrob Agents. 2013;59(10):6471–6476.
4. Falagas ME, Vouloumanou EK, Samonis G, et al. Fosfomycin. Clin Microbiol Rev. 2016;29:321–347.
5. Castaneda-Garcia A, Blazquez J, Rodriguez-Rojas A., Molecular mechanisms and clinical impact of acquired and intrinsic fosfomycin resistance. Antibiotics (Basel, Switzerland). 2013;2(2):217–236.
6. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 7.1, 2017. http://www.eucast.org.
7. Datapharm Communications Limited, Electronic Medicines Compendium (eMC). Fomicyt 40 mg/ml powder for solution for infusion. 2014. https://www.medicines.org.uk/emc/medicine/28971
8. Zavante Therapeutics. Safety and efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections (ZEUS). Bethesda (MD): National Library of Medicine (US); 2016. NLM Identifier: 02753946. Available form: www.ClinicalTrials.gov
9. Docobo-Perez F, Drusano GL, Johnson A, et al. Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance. Antimicrob Agents Chemother. 2015;59(9):5602–5610.
10. Bhavnani S, Trang M, Rubino C, et al. Pharmacokinetics-Pharmacodynamics (PK-PD) target attainment analyses to support ZTI-01 (fosfomycin for injection) dose selection for patients with complicated urinary tract infections. In: ASM microbe. New Orleans (LA); 2017.
11. Sastry S, Doi Y., Fosfomycin: resurgence of an old companion. J Infect Chemother. 2016;22:273–280.
12. Parker SL, Frantzeskaki F, Wallis SC, et al. Population pharmacokinetics of fosfomycin in critically ill patients. Antimicrob Agents Chemother. 2015;59:6471–6476.
13. Yu X-H, Song X-J, Cai Y, et al. In vitro activity of two old antibiotics against clinical isolates of methicillin-resistant Staphylococcus aureus. J Antibiot. 2010;63(11):657–659.
14. Vardakas KZ, Legakis NJ, Triarides N, et al. Susceptibility of contemporary isolates to fosfomycin: a systematic review of the literature. Int J Antimicrob Agents. 2016;47(4):269–285.
15. Jiang Y, Shen P, Wei Z, et al. Dissemination of a clone carrying a fosA3-harbouring plasmid mediates high fosfomycin resistance rate of KPC-producing Klebsiella pneumoniae in China. Int J Antimicrob Agents. 2015;45(1):66–70.
16. Endimiani A, Patel G, Hujer KM, et al. In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin. Antimicrob Agents Chemother. 2010;54(1):526–529.
17. Castanheira M, Griffin MA, Deshpande LM, et al. Detection of mcr-1 among Escherichia coli clinical isolates collected worldwide as part of the SENTRY antimicrobial surveillance program in 2014 and 2015. Antimicrob Agents Chemother. 2016;60(9):5623–5624.
18. Dinh A, Salomon J, Bru JP, et al. Fosfomycin: efficacy against infections caused by multidrug-resistant bacteria. Scand J Infect Dis. 2012;44:182–189.
19. Pontikis K, Karaiskos I, Bastani S, et al. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. Int J Antimicrob Agents. 2014;43:52–59.
20. Apisarnthanarak A, Mundy LM. Use of high-dose 4-hour infusion of doripenem, in combination with fosfomycin, for treatment of carbapenem-resistant Pseudomonas aeruginosa pneumonia. Clin Infect Dis. 2010;51(11):1352–1354.
21. Apisarnthanarak A, Mundy LM. Carbapenem-resistant Pseudomonas aeruginosa pneumonia with intermediate minimum inhibitory concentrations to doripenem: combination therapy with high-dose, 4-h infusion of doripenem plus fosfomycin versus intravenous colistin plus fosfomycin. Int J Antimicrob Agents. 2012;39:271–272.
22. Sirijatuphat RTV. Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother. 2014;58(9):5598–5601.
23. Perez F, El Chakhtoura NG, Papp-Wallace KM, et al. Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply “precision medicine” to antimicrobial chemotherapy? Expert Opin Pharmacother. 2016;17(6):761–781.
24. Rodriguez-Bano J, Cisneros JM, Cobos-Trigueros N, et al. Diagnosis and antimicrobial treatment of invasive infections due to multidrug-resistant Enterobacteriaceae. Guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology. Enferm Infecc Microbiol Clin. 2015;33(5):337.e331–337.e321.
25. Roberts JA, Abdul-Aziz MH, Lipman J, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014;14:498–509.
26. Kirby W. Pharmacokinetics of fosfomycin. Chemotherapy. 1977;23:141–151.
27. Farago E, Kiss I, Nabradi Z. Serum and lung tissue levels of fosfomycin in humans. Int J Clin Pharmacol Ther Toxicol. 1980;18:554–558.
28. Berthelot G, Bergogne-Berezin E, Kafe H, et al. Penetration of fosfomycin into bronchial secretions. Pathol Biol (Paris). 1983;31:519–521.
29. Matzi V, Lindenmann J, Porubsky C, et al. Extracellular concentrations of fosfomycin in lung tissue of septic patients. J Antimicrob Chemother. 2010;65:995–998.
30. Pfeifer G, Frenkel C, Entzian W. Pharmacokinetic aspects of cerebrospinal fluid penetration of fosfomycin. Int J Clin Pharmacol Res. 1985;5(3):171–174.
31. Simkins J, Fan J, Camargo JF, et al. Intravenous fosfomycin treatment for carbapenem-resistant Klebsiella pneumoniae in the United States. Ann Pharmacother. 2015;49(10):1177–1178.
32. Michalopoulos A, Virtzili S, Rafailidis P, et al. Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin Microbiol Infect. 2010;2010(16):2.
33. Florent A, Chichmanian RM, Cua E, et al. Adverse events associated with intravenous fosfomycin. Int J Antimicrob Agents. 2011;37:82–83.
34. Kusachi S, Nagao J, Saida Y, et al. Antibiotic time-lag combination therapy with fosfomycin for postoperative intra-abdominal abscesses. J Infect Chemother. 2011;17(1):91–96.
35. Navarro-San Francisco C, Mora-Rillo M, Romero-Gómez MP, et al. Bacteraemia due to OXA-48-carbapenemase-producing Enterobacteriaceae: a major clinical challenge. Clin Microbiol Infect. 2013;19:E72-E79.
36. del Río A, Gasch O, Moreno A, et al. Efficacy and safety of fosfomycin plus imipenem as rescue therapy for complicated bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus: a multicenter clinical trial. Clinical Infect Dis. 2014;59:1105–1112.
37. Chen J, Luo Y, Zhang S, et al. Community-acquired necrotizing pneumonia caused by methicillin-resistant Staphylococcus aureus producing Panton-Valentine leukocidin in a Chinese teenager: case report and literature review. Int J Infect Dis. 2014;26:17–21.
38. Chen L-Y, Huang C-H, Kuo S-C, et al. High-dose daptomycin and fosfomycin treatment of a patient with endocarditis caused by daptomycin-nonsusceptible Staphylococcus aureus: case report. BMC Infect Dis. 2011;11:152.
39. Karageorgopoulos DE, Miriagou V, Tzouvelekis LS, et al. Emergence of resistance to fosfomycin used as adjunct therapy in KPC Klebsiella pneumoniae bacteraemia: report of three cases. J Antimicrob Chemother. 2012;67(11):2777–2779.
40. Vergara-Lopez S, Dominguez M, Conejo M, et al. Prolonged treatment with large doses of fosfomycin plus vancomycin and amikacin in a case of bacteraemia due to methicillin-resistant Staphylococcus epidermidis and IMP-8 metallo-beta-lactamase-producing Klebsiella oxytoca. J Antimicrob Chemother. 2015;70(1):313–315.
41. Miro JM, Entenza JM, Del Rio A, et al. High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 2012;56(8):4511–4515.
42. Knaus WA, Draper EA, Wagner DP, et al. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13(10):818–829.
43. Vincent JL, de Mendonca A, Cantraine F, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on “sepsis-related problems” of the European Society of Intensive Care Medicine. Crit Care Med. 1998;26(11):1793–1800.
44. Shaw E, Miró JM, Puig-Asensio M, et al. Daptomycin plus fosfomycin versus daptomycin monotherapy in treating MRSA: protocol of a multicentre, randomised, phase III trial. BMJ Open. 2015;5:e006723.
45. Karageorgopoulos DE, Wang R, Xu-Hong Y, et al. Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens. J Antimicrob Chemother. 2012;67(2):255–268.
46. Vincent JL, Marshall J, Anzueto A, et al. and outcomes of infection in intensive care units. JAMA. 2009;302:2323–2329.
47. Weiner LM, Fridken SK, Aponte-Torres Z, et al. Vital signs: preventing antibiotic-resistant infections in hospitals - United States, 2014. MMWR Morb Mortal Wkly Rep. 2016;65(9):235–241.
48. Livermore DM. Current epidemiology and growing resistance of gram-negative pathogens. Korean J Intern Med. 2012;27(2):128–142.
49. Kanj SS, Kanafani ZA. Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clin Proc. 2011;86(3):250–259.
50. Sheng WH, Liao CH, Lauderdale TL, et al. A multicenter study of risk factors and outcome of hospitalized patients with infections due to carbapenem-resistant Acinetobacter baumannii. Int J Infect Dis. 2010;14:e764–e769.
51. Tacconelli E, Tumbarello M, Bertagnolio S, et al. Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: analysis of trends in prevalence and epidemiology international conference on emerging infectious diseases, 2002. Emerg Infect Dis. 2002;8:8–9.
52. Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61–e111.
53. Fundación Pública Andaluza para la gestión de la Investigación en Sevilla. Spanish Network for Research in Infectious Diseases. Fosfomycin Versus Meropenem or Ceftriaxone in Bacteriemic Infections Caused by Multidrug Resistance in E. coli (FOREST). ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2016
54. Kawabata T, Yokota M, Mayama T, et al. A post-marketing surveillance study of fosfomycin sodium for injectionA nationwide prospective study of safety in 100, 000 cases. Jpn J Chemother. 2000;48(11):851–874.
55. Coukell A, Shore C. A scientific roadmap for antibiotic discovery. 2016. http://www.pewtrusts.org/~/media/assets/2016/05/ascientificroadmapforantibioticdiscovery.pdf
56. Davey PG, Marwick C. Appropriate vs. inappropriate antimicrobial therapy. Clin Microbiol Infect. 2008;14(Suppl 3):15–21.